Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population
出版年份 2018 全文链接
标题
Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population
作者
关键词
Estimated glomerular filtration rate, Glucagon-like peptide-1 receptor agonists, Glycated hemoglobin, Renal impairment
出版物
Diabetes Therapy
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2018-02-19
DOI
10.1007/s13300-018-0377-5
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes
- (2017) Mukul Singhal et al. Journal of Managed Care & Specialty Pharmacy
- Comment on Fischer et al. Text Message Support for Weight Loss in Patients With Prediabetes: A Randomized Clinical Trial. Diabetes Care 2016;39:1364–1370
- (2016) Mohsen Afarideh et al. DIABETES CARE
- Response to Comment on Crews et al. Role and Determinants of Adherence to Off-loading in Diabetic Foot Ulcer Healing: A Prospective Investigation. Diabetes Care 2016;39:1371–1377
- (2016) Ryan T. Crews et al. DIABETES CARE
- Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials
- (2016) Katherine R. Tuttle et al. DIABETES OBESITY & METABOLISM
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictors of glycemic control and diabetes-related costs among type 2 diabetes patients initiating therapy with liraglutide in the United States
- (2016) Emily Durden et al. JOURNAL OF MEDICAL ECONOMICS
- Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial
- (2016) Sanjay Kalra Diabetes Therapy
- Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial
- (2016) Sanjay Kalra Diabetes Therapy
- Hypoglycemia in Patients with Diabetes and Renal Disease
- (2015) Mazen Alsahli et al. Journal of Clinical Medicine
- Cardiovascular Complications of Diabetic Kidney Disease
- (2014) Ragnar Pálsson et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- Improved real-world glycaemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes
- (2014) W. C. Lee et al. DIABETES OBESITY & METABOLISM
- Efficacy of Liraglutide in a Real-Life Cohort
- (2014) Anthony Heymann et al. Diabetes Therapy
- Real-World Clinical and Economic Outcomes of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Mellitus in the United States
- (2014) Qian Li et al. Diabetes Therapy
- The INITIATOR Study: Pilot Data on Real-World Clinical and Economic Outcomes in US Patients with Type 2 Diabetes Initiating Injectable Therapy
- (2013) Sarah Thayer et al. ADVANCES IN THERAPY
- A New Equation to Estimate Glomerular Filtration Rate
- (2013) Andrew S. Levey et al. ANNALS OF INTERNAL MEDICINE
- GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure
- (2013) Minsuk Kim et al. NATURE MEDICINE
- Automated Detection and Classification of Type 1 Versus Type 2 Diabetes Using Electronic Health Record Data
- (2012) M. Klompas et al. DIABETES CARE
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
- (2012) John B Buse et al. LANCET
- GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases
- (2012) Hari Hendarto et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Beyond glucose lowering: Glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system
- (2011) B. Vergès et al. DIABETES & METABOLISM
- The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats
- (2010) Que Liu et al. Cardiovascular Diabetology
- Chronic Administration of the Glucagon-Like Peptide-1 Analog, Liraglutide, Delays the Onset of Diabetes and Lowers Triglycerides in UCD-T2DM Rats
- (2010) B. P. Cummings et al. DIABETES
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started